While it has previously been demonstrated that the inhibition of SIRT2 reduces astrocyte reactivity markers [40] and rescues α-synuclein-mediated toxicity in Parkinson’s Disease models [30], our study is the first to identify the metabolic step catalyzed by SIRT2 in reactive astrocytes. The gene discussed is SIRT2; the disease is Parkinson disease.